

## **The deficiency of galectin-3 in stromal cells leads to enhanced tumor growth and bone marrow metastasis**

Jonathas Xavier Pereira<sup>1</sup>, Maria Carolina Braga de Azeredo<sup>2</sup>, Felipe Sá Martins<sup>3</sup>, Roger Chammas<sup>4</sup>, Felipe Leite de Oliveira<sup>5</sup>, Sofia Nascimento dos Santos<sup>6</sup>, Emerson Soares Bernardes<sup>7</sup> and Márcia Cury El Cheikh<sup>8</sup>.

1. Pereira, JX. Programa de Pós-Graduação em Anatomia Patológica, Hospital Clementino Fraga Filho, UFRJ, Rio de Janeiro, Brasil. E-mail: jonathasxp@gmail.com
2. Azeredo, MCB. Programa de Pós-Graduação em Ciências Morfológicas, ICB, UFRJ, Rio de Janeiro, Brasil. E-mail: mcbazeredo@yahoo.com.br
3. Martins, FS. Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil. E-mail: felipedesa.farma@gmail.com
4. Chammas, R. Laboratório de Oncologia Experimental e Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina, São Paulo, Brasil. E-mail: rchammas@usp.br
5. Oliveira, FL. Laboratório de Proliferação e Diferenciação Celular, ICB, UFRJ, Brasil. E-mail: felipe@histo.ufrj.br
6. Santos, SN. Centro de Radiofarmácia, Instituto de Pesquisas Energéticas e Nucleares (IPEN), São Paulo, Brasil. E-mail: snsantos85@gmail.com
7. Bernardes, ES. Centro de Radiofarmácia, Instituto de Pesquisas Energéticas e Nucleares (IPEN), São Paulo, Brasil. E-mail: emerson.bernardes@gmail.com
8. El-Cheikh, MC (\*). Laboratório de Proliferação e Diferenciação Celular, ICB, UFRJ, Brasil. E-mail: marcia@histo.ufrj.br

1 and 2, both contributed equally for the work

(\*) Corresponding author. Av. Carlos Chagas Filho, 393. Bloco F. CEP. 21941-902. Cidade Universitária, Ilha do Fundão, Instituto de Ciências Biomédicas, CCS, Rio Janeiro, RJ, Brasil. e-mail: marcia@histo.ufrj.br.

## **Additional file 3**

### **Additional file Figures legend**

**Additional file 1: Figure S1.** Immunohistochemistry to localize Galectin-3 in primary tumor and in peri-tumoral area Lgals-3<sup>+/+</sup> and Lgals-3<sup>-/-</sup> female mice. (A and C) Tumor of Lgals-3<sup>+/+</sup> of after 21 and 28 days p.o.i. (B and D) Tumor of Lgals-3<sup>-/-</sup> of after 21 and 28 days p.o.i. (E) quantification of galectin-3 positive cells in primary tumor and in peri-tumoral tissue (\*). Data are the mean  $\pm$  S.D., n=4, three animals per group; \*\*\* p<0.001.

**Additional file 2: Figure S2.** 4T1 cells express galectin-3, CK-19 and CXCR4 proteins. Representative immunocytochemical staining of (a) galectin-3 (b) CK-19 and (c) CXCR4. The negative control of each reaction is represented in the figures (\*).

### **Supplemental methods**

#### **Supplemental methods 1**

##### **Immunohistochemistry in the primary tumors.**

Primary tumors were fixed in 4% paraformaldehyde and stained with anti-galectin-3 (M3/38 monoclonal antibody, ATCC, USA) followed by a secondary anti-rat biotinylated antibodies. Next, avidin-peroxidase (Sigma-Aldrich, USA) was added and color development was done with diaminobenzidine. The positive cells were quantified in three random fields inside and in peri-tumoral area by TMarker software.

## **Supplemental methods 2**

### **Immunocytochemistry of 4T1 cells**

4T1 cells were fixed in 4% paraformaldehyde and stained with anti-CK-19 (purified polyclonal antibody – Abcam), anti-galectin-3 (M3/M8 polyclonal antibody, ATCC, USA) and anti-CXCR4 (purified polyclonal antibody – Abcam) followed by a secondary anti-rabbit or anti-rat biotinylated antibodies. Next, avidin-peroxidase (Sigma-Aldrich, USA) was added and color development was done with diaminobenzidine. As a negative control, the same procedure was used without the primary antibody.